1. A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (12th June 2019) Authors: Kalakonda, N.; Cavallo, F.; Follows, G.; Goy, A.; Vermaat, J.; Casasnovas, O.; Lavee, O.; Maerevoet, M.; Zijlstra, J.; Bakshi, S.; Bouabdallah, R.; Choquet, S.; Gurion, R.; Hill, B.; Jaeger, U.; Sancho, J.; Schuster, M.; Thieblemont, C.; De la Cruz, F.; Egyed, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL. (12th June 2019) Authors: Jacobsen, E.; Ďuraš, J.; Ardeshna, K.; Cherry, M.; Offner, F.; Mayer, J.; Bijou, F.; Tani, M.; Musuraca, G.; Merli, M.; Marasca, R.; Weaver, D.T.; Lustgarten, S.; Youssoufian, H.; Zinzani, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 400 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO. (12th June 2019) Authors: Gribben, J.; Trneny, M.; Izutsu, K.; Fowler, N.H.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.; Scheinberg, P.; Flinn, I.; Moreira, C.; Czuczman, M.; Kalambakas, S.; Fustier, P.; Wu, C.; Leonard, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FIVE‐YEAR FOLLOW‐UP OF FIRST‐LINE IBRUTINIB FOR TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA//SMALL LYMPHOCYTIC LYMPHOMA. (12th June 2019) Authors: Tedeschi, A.; Burger, J.; Barr, P.M.; Robak, T.; Owen, C.; Ghia, P.; Bairey, O.; Hillmen, P.; Coutre, S.; Devereux, S.; Grosicki, S.; McCarthy, H.; Li, J.; Simpson, D.; Offner, F.; Moreno, C.; Dai, S.; Lal, I.; Dean, J.P.; Kipps, T.J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL. (12th June 2019) Authors: Ghia, P.; Flinn, I.W.; Lamanna, N.; Montillo, M.; Illés, Á.; Etienne, G.; Delgado, J.; Kuss, B.J.; Tam, C.S.; Offner, F.; Bosch, F.; Davids, M.S.; Jäger, U.; Cymbalista, F.; Weaver, D.T.; Lustgarten, S.; Youssoufian, H.; Stilgenbauer, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO (AUGMENT). (12th June 2019) Authors: Thieblemont, C.; Leonard, J.; Trneny, M.; Izutsu, K.; Fowler, N.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.; Scheinberg, P.; Flinn, I.; Moreira, C.; Czuczman, M.; Kalambakas, S.; Fustier, P.; Wu, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS. (12th June 2019) Authors: Leonard, J.; Trneny, M.; Izutsu, K.; Fowler, N.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.; Scheinberg, P.; Flinn, I.; Moreira, C.; Czuczman, M.; Kalambakas, S.; Fustier, P.; Wu, C.; Gribben, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. HEALTH‐RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2) VERSUS R PLUS PLACEBO. (12th June 2019) Authors: Leonard, J.P.; Trněny, M.; Izutsu, K.; Fowler, N.H.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.M.; Scheinberg, P.; Flinn, I.W.; Moreira, C.; Tabah, A.; Abouzaid, S.; Kalambakas, S.; Fustier, P.; Wu, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 232 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. GENE‐EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. (June 2017) Authors: Huet, S.; Tesson, B.; Jais, J.; Feldman, A.L.; Magnano, L.; Thomas, E.; Traverse‐Glehen, A.; Albaud, B.; Xerri, L.; Ansell, S.; Tarte, K.; Boyault, S.; Haioun, C.; Link, B.; Feugier, P.; Lopez‐Guillermo, A.; Brice, P.; Hayette, S.; Jardin, F.; Offner, F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 7‐YEAR RESULTS FROM RESONATE‐2. (17th June 2021) Authors: Coutre, S. E.; Barr, P. M.; Owen, C.; Robak, T.; Tedeschi, A.; Bairey, O.; Burger, J. A.; Hillmen, P.; Devereux, S.; Grosicki, S.; McCarthy, H.; Li, J.; Simpson, D.; Offner, F.; Moreno, C.; Dai, S.; Szoke, A.; Dean, J. P.; Kipps, T. J.; Ghia, P. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗